| Product Unit Size | Cost | Quantity | Stock |
|---|
Darifenacin is an inhibitor of M3 muscarinic acetylcholine receptors (mAChRs) that is used to treat overactive bladder. Darifenacin’s inhibition of M3 mAChRs inhibits smooth muscle contraction, potentially involving downstream modulation of PLC and PKA signaling.
| Cas No. | 133099-07-7 |
|---|---|
| Purity | ≥98% |
| Formula | C28H30N2O2 • HBr |
| Formula Wt. | 507.46 |
| IUPAC Name | 2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2, 2-diphenylacetamide;hydrobromide |
| Synonym | Darifenacin hydrobromide |
| Melting Point | 228-230°C |
| Appearance | White to off white powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Matsumoto Y, Miyazato M, Yokoyama H, et al. Role of M2 and M3 muscarinic acetylcholine receptor subtypes in activation of bladder afferent pathways in spinal cord injured rats. Urology. 2012 May;79(5):1184.e15-20. PMID: 22386753.
Hegde SS. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol. 2006 Feb;147 Suppl 2:S80-7. PMID: 16465186.
Braverman AS, Tibb AS, Ruggieri MR Sr. M2 and M3 muscarinic receptor activation of urinary bladder contractile signal transduction. I. Normal rat bladder. J Pharmacol Exp Ther. 2006 Feb;316(2):869-74. PMID: 16243961.